Dynavax Technologies Corporation (NASDAQ: DVAX)
$12.8100
-0.0200 ( -0.08% ) 132.7K
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Market Data
Open
$12.8100
Previous close
$12.8300
Volume
132.7K
Market cap
$1.67B
Day range
$12.7250 - $12.8400
52 week range
$9.7400 - $15.0100
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Nov 12, 2024 |
10-q | Quarterly Reports | 78 | Nov 07, 2024 |
8-k | 8K-related | 15 | Nov 07, 2024 |
8-k | 8K-related | 16 | Oct 29, 2024 |
3 | Insider transactions | 1 | Oct 24, 2024 |
10-q | Quarterly Reports | 75 | Aug 06, 2024 |
8-k | 8K-related | 13 | Aug 06, 2024 |
8-k | 8K-related | 11 | Aug 02, 2024 |
4 | Insider transactions | 1 | Jun 03, 2024 |
4 | Insider transactions | 1 | May 28, 2024 |